Navigation Links
Timing of first menstrual cycle may be predictor of cardiovascular disease risk in women
Date:11/13/2012

Chevy Chase, MDAge at onset of menarche (first menstrual cycle) is associated with increased body mass index (BMI), waist circumference, and overall obesity in adulthood, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

Cardiovascular disease (CVD) is the leading cause of death in women in the United States. When compared to men, women may manifest their clinical disease later in life, rendering standard risk prediction algorithms less reliable in women. The current study uses a life course approach, which looks for associations between earlier life events and later health outcomes, to better understand and predict CVD risk in women at their pre-clinical stage.

"The purpose of this study was to examine whether female reproductive risk factors including onset of menarche, number of births over a lifetime (called parity), onset of menopause, and menopausal status are associated with indices of body fat composition," said Caroline S. Fox, MD, MPH, of the National Heart, Lung, and Blood Institute, and senior author of the study. "We found that earlier onset of menarche is associated with overall adiposity, whereas parity and menopausal age were not associated with adiposity measures. Post-menopausal women also had higher levels of overall adiposity, though this appeared to be mostly due to age and not menopausal status."

The study featured 1,638 women who participated in the Framingham Heart Study (FHS) between 2002 and 2005. These participants were aged 40 or older, weighed less than 160 kg and not pregnant. Study participants underwent a physical exam along with laboratory analyses to measure visceral adiposity (VAT, the "belly fat" around the abdomen) and subcutaneous adiposity (SAT, the fat under the skin). The study modeled the relationship between VAT, SAT, and female reproductive factors after adjusting for age, smoking status, alcohol intake, physical activity index, hormone replacement therapy and menopausal status. Results of the study showed the timing of the first menstrual cycle was associated with generalized but not regional body fat depots.

"This research suggests that select female reproductive risk factors, specifically onset of menarche, are associated with overall adiposity, but not with specific indices of body fat distribution," said Dr. Subbulaxmi Trikudanathan, of Harvard Medical School in Boston, MA, and lead author of the study . "Ultimately, the important question is whether female reproductive risk factors can be used to target lifestyle interventions in high risk women to prevent the metabolic consequences of obesity and cardiovascular disease."


'/>"/>

Contact: Aaron Lohr
alohr@endo-society.org
240-482-1380
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Timing of antibiotics important in reducing infections after C-section
2. Mount Sinai researcher finds timing of ADHD medication affect academic progress
3. Timing pregnancy an important health concern for women
4. First-of-its-kind program improves outcomes for seniors admitted for trauma
5. First trial in humans of minicells: A completely new way of delivering anti-cancer drugs
6. AIUM 2013 Annual Convention provides an in-depth look into ultrasound first
7. First comprehensive guidelines for managing anaplastic thyroid cancer published in Thyroid journal
8. First gene therapy study in human salivary gland shows promise
9. Clinical trials for first-ever human hookworm vaccine advance
10. Handshakes Matter for First Impressions, Brain Study Confirms
11. IU researchers report first effective treatment of tumors arising from common genetic disease NF1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... compare student test score performance for the 2015-16 school year across Wisconsin’s public ... programs. Though it highlights important patterns in student test score performance, the report’s ...
(Date:4/25/2017)... ... 25, 2017 , ... As pharmaceutical companies are held to ... process innovation in drug formulation and manufacturing. CoreRx offers its clients more ... in support of their development and manufacturing goals. , The company was ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the ... or chronic problems, I focus on preventative care with all my patients to alleviate possible ... questions, always feel free to contact my office and my trained staff will assist you ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Conference at the InterContinental Hotel in Boston, ... Biomet will present at 11:20 a.m. Eastern Time. ... accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... -- Research and Markets has announced the addition of ... Expanding Injectables Market and Increasing Usage of Complex Biologics during the ... ... from USD 20 Billion in 2015 to around USD 26 Billion ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
Breaking Medicine Technology: